Abstract:Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is an uncommon primary liver malignancy and little known about the clinical and imaging characteristics of cHCC-CC. We aim to define the demographics, imaging features of cHCC-CC on contrast-enhanced ultrasound (CEUS) and contrast-enhanced computed tomography (CT) in this study. Methods: From January 2005 to December 2014, 45 patients with pathologically proven cHCC-CC who underwent preoperative CEUS and 43 patients who had additional CT scan in our institution were included. A retrospective review of the imaging studies and clinical data in these patients was conducted. Results: In our series, cHCC-CC accounted for 1.6 % of all primary liver malignancy. Mean age of patient with cHCC-CC was 52.8 year (range: 28-74 year) and 88.9 % (40/45) of patients were male. Thirty of forty five patients (66.7 %) had cirrhosis and 20 % (9/45) of patients had chronic hepatitis B without cirrhosis. Alpha--fetoprotein (AFP) was elevated in 62.2 % (28/45) of patients and carbohydrate antigen 19-9 (CA19-9) elevated in 22.2 % (10/45) of patients). Both AFP and CA19-9 were simultaneously elevated in 15.6 % (7/45) of patients. Enhancement pattern resembling cholangiocarcinoma (CC) was noted in 53.3 % (24/45) of patients (on CEUS and in 30.2 % (13/43) of patients at CT. Enhancement pattern resembling hepatocellular carcinoma (HCC) was observed in 42.2 % (19/45) of patients on CEUS and in 58.1 % (25/43) of patients at CT. The percentage of tumors showing CC enhancement pattern (27.9 %, 12/43) was comparable with that of tumors showing HCC enhancement pattern (44.2 %, 19/43) on both CEUS and CT (p = 0.116). Simultaneous elevation of tumor markers (AFP and CA19-9) or tumor marker elevation (AFP or CA19-9) in discordance with enhancement pattern on CEUS was demonstrated in 51.1 % (23/45) of patients and on CT in 53.5 % (23/43) of patients, which was significantly more than simultaneous elevation of tumor markers (AFP and CA19-9) alone (p = 0.000). Conclusions: The clinical characteristics of cHCC-CC are similar to those of HCC. The cHCC-CC tumors display enhancement patterns resembling CC or HCC in comparable proportion on both CEUS and CT. Combination of simultaneous elevation of tumor makers (AFP and CA19-9) and tumor mark elevation (AFP or CA19-9) in discordance with presumptive imaging findings on CEUS or CT may lead significantly more patients to be suspicious of the diagnosis of cHCC-CC.

Advances in imaging diagnosis of mixed-type liver cancer

Contrast-enhanced Multiple-Phase Imaging Features of Intrahepatic Mass-Forming Cholangiocarcinoma and Hepatocellular Carcinoma with Cirrhosis: A Comparative Study

Emerging Biomolecules for Practical Theranostics of Liver Hepatocellular Carcinoma.

Accurate imaging diagnosis and evaluation of pancreatic cancer

Ultrasonography of Hepatocellular Carcinoma: From Diagnosis to Prognosis

Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma

Contrast enhanced ultrasound in mixed hepatocellular cholangiocarcinoma: Case series and review of the literature.

[Current status and new advancements in molecular imaging of liver cancer]

Advances in the Imaging Evaluation of Cholangiocarcinoma

[New Advances in the Diagnosis and Treatment of Intrahepatic Cholangiocarcinoma].

Two case reports of breast cancer combined with synchronous primary intrahepatic cholangiocarcinoma/mixed liver cancer

Imaging Features Of Intrahepatic Mass-Forming Cholangiocarcinomas On Gd-Bopta-Enhanced Mri

Radiomics in the Diagnosis and Treatment of Hepatocellular Carcinoma

Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI

The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma

Clinical Characteristics and Prognosis of Mixed Hepatocellular Carcinoma and Cholangiocarcinoma

Clinical characteristics and prognosis of 26 cases of combined hepatocellular carcinoma and cholangiocarcinoma

Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography

Combined Hepatocellular Cholangiocarcinoma: Controversies to Be Addressed.

[Research progress and prospects of the application of radiographic imaging in the precise diagnosis and treatment of hepatocellular carcinoma]